Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reactogenecity of indigenously produced measles vaccine

I Bhargava1, B C Chhaparwal, M A Phadke

  • 1Serum Institute of India Research Foundation, Pune.

Indian Pediatrics
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.

Human vaccines & immunotherapeutics·2015
Same author

Polio eradication for India: shift of focus.

Vaccine·2008
Same author

Non-physician clinicians in India.

Lancet (London, England)·2008
Same author

Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.

Clinical and vaccine immunology : CVI·2007
Same author

Blood tests for diagnosis of tuberculosis.

Lancet (London, England)·2006
Same author

Profile of bone marrow examination in HIV/AIDS patients to detect opportunistic infections, especially tuberculosis.

Indian journal of pathology & microbiology·2006

The indigenously produced measles vaccine from EZ strain is safe and well-tolerated in children. Mild side effects were observed, with neurological events being rare and without sequelae.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Measles vaccination is crucial for public health.
  • Assessing the safety and reactogenicity of new vaccine strains is essential.

Purpose of the Study:

  • To evaluate the safety and reactogenicity of an indigenously produced measles vaccine derived from the EZ strain.
  • To compare its safety profile with existing vaccines.

Main Methods:

  • A longitudinal clinical follow-up study was conducted.
  • 12,470 children aged 9-15 months received the EZ strain measles vaccine.
  • Clinical and neurological examinations were performed at multiple time points post-vaccination.

Main Results:

  • 31% of children experienced mild side effects, predominantly within the first two weeks.

Related Experiment Videos

  • Common side effects included coryza, fever, cough, and diarrhea.
  • Only two cases of convulsions with no sequelae were reported.

    • Conclusions:

    • The Indian-manufactured measles vaccine using the EZ strain is safe.
    • Its reactogenicity, including neurological aspects, is lower than the Schwarz strain vaccine previously reported in India.